Published : 27 February, 2018
Blood Screening refers to examining the donor blood in test centers prior to transfusion or transmission to a recipient. All the tests have to show that the blood is free of any infectious disease before it is sent to hospitals and blood banks for use as this is the only way to reduce associated risks. Blood screening has been made mandatory in 30 countries keeping in mind the health effects on the recipients. Some of the common tests for blood screening include:-
• Babesia (babesia microti)
• Hepatitis B virus (HBV)
• Hepatitis C virus (HCV)
• Human Immunodeficiency viruses, Type 1 and 2 (HIV 1,2)
• Human T-Lymphotropic virus
• Zika virus
The North American continent holds the highest share of almost 47% in the blood screening market mainly on the back of awareness, regulation and sophisticated medical systems. Around 13.6 million units of blood is collected by around 6.8 million blood donors a year in the US alone.
The Global Blood Screening Market is expected to reach USD 3.06 Billion by the year 2022 from USD 2.35 Billion in 2017 witnessing a growth of 4.46% over the same period. The NAT (Nucleic Acid Test) holds the highest share. The NAT segment is attracting significant investments due to the application of these tests in various other diseases like cancer, infectious diseases etc.
In our report, the entire market is analyzed in segments like:-
3) Products and services
Visit this link to know more about our report:-http://genesismarketinsights.com/viewreport/75/28/Blood-Screening-Market
(+91) 20 25447724